If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

[89] The beneficial effect of the treatment is associated with a reduction in serum levels of IL-1β and TNF-α and, occasionally, with amelioration of neutropenia substantiating the important ...

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025Right-sizing commercial efforts to ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.